These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 26950187)

  • 1. Is rituximab retro in mantle cell lymphoma?
    Ryan CE; Cohen JB
    Blood; 2024 Jul; 144(3):241-243. PubMed ID: 39023870
    [No Abstract]   [Full Text] [Related]  

  • 2. Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era.
    Arushi Khurana ; Mwangi R; Ansell SM; Habermann TM; Cerhan JR; Strouse C; Link BK; Wang Y; King RL; Macon WR; Villasboas JC; Witzig TE; Maurer MJ; Nowakowski GS
    Blood Cancer J; 2021 Jul; 11(7):133. PubMed ID: 34274939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The aggravating fury rituximab obliterated.
    Mahadevia H; Al-Obaidi A; Cossor F
    Haematologica; 2024 Jun; 109(6):2016-2018. PubMed ID: 38268447
    [No Abstract]   [Full Text] [Related]  

  • 4. Double-hit, double-expressor follicular lymphoma with plasmacytic differentiation.
    Nabeel H; Bhagat G
    Blood; 2024 Jul; 144(3):339. PubMed ID: 39023868
    [No Abstract]   [Full Text] [Related]  

  • 5. Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos.
    Zala M; Lipinski B; Costechareyre C; Jarrosson L; Teinturier R; Julia E; Lacourrège M; Verney A; Guitton J; Traverse-Glehen A; Bachy E; Salles G; Huet S; Genestier L; Castellani V; Delloye-Bourgeois C; Sujobert P
    Leukemia; 2024 Feb; 38(2):430-434. PubMed ID: 38225454
    [No Abstract]   [Full Text] [Related]  

  • 6. Is There a Best Initial Treatment for a New Patient With Low Grade Follicular Lymphoma.
    Jacobson CA; Freedman AS
    Curr Hematol Malig Rep; 2016 Jun; 11(3):218-23. PubMed ID: 26995595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular lymphoma: evolving therapeutic strategies.
    Kahl BS; Yang DT
    Blood; 2016 Apr; 127(17):2055-63. PubMed ID: 26989204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in high risk diffuse large cell B-cell lymphoma patients as a first line treatment.
    Schwarzbich MA; Schöning T; Cremer M; Lisenko K; Ho AD; Witzens-Harig M
    Leuk Lymphoma; 2016 Jul; 57(7):1723-6. PubMed ID: 26980422
    [No Abstract]   [Full Text] [Related]  

  • 9. Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
    Eyre TA; Linton KM; Rohman P; Kothari J; Cwynarski K; Ardeshna K; Bailey C; Osborne WL; Rowntree C; Eden D; Shankara P; Eyre DW; Jasani P; Chaidos A; Collins GP; Hatton CS
    Br J Haematol; 2016 Jun; 173(6):896-904. PubMed ID: 26956150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
    Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
    Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.
    Casadei B; Pellegrini C; Pulsoni A; Annechini G; De Renzo A; Stefoni V; Broccoli A; Gandolfi L; Quirini F; Tonialini L; Morigi A; Argnani L; Zinzani PL
    Cancer Med; 2016 Jun; 5(6):1093-7. PubMed ID: 26990782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.
    Freeman CL; Dixon M; Houghton R; Kreuzer KA; Fingerle-Rowson G; Herling M; Humphrey K; Böttcher S; de Costa CS; Iglesias V; Stilgenbauer S; Gribben J; Hallek M; Goede V
    Leukemia; 2016 Aug; 30(8):1763-6. PubMed ID: 26979130
    [No Abstract]   [Full Text] [Related]  

  • 13. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
    Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
    Williams ME; Hong F; Gascoyne RD; Wagner LI; Krauss JC; Habermann TM; Swinnen LJ; Schuster SJ; Peterson CG; Sborov MD; Martin SE; Weiss M; Ehmann WC; Horning SJ; Kahl BS
    Br J Haematol; 2016 Jun; 173(6):867-75. PubMed ID: 26970533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD markers polymorphisms as prognostic biomarkers in hematological malignancies.
    Shahrabi S; Ghanavat M; Behzad MM; Purrahman D; Saki N
    Oncol Rev; 2020 Jul; 14(2):466. PubMed ID: 32782727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer.
    Sordo-Bahamonde C; Lorenzo-Herrero S; Payer ÁR; Gonzalez S; López-Soto A
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients.
    Gutiérrez-Cívicos R; Hurtado AM; Torres-Moreno D; Sanchez-Blanco JJ; Español I; Consuegra-Sánchez L; Perez-Ceballos E; Gutiérrez-Meca MD; Jerez A; Conesa-Zamora P
    Am J Hematol; 2016 Jun; 91(6):E305-7. PubMed ID: 26950187
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
    Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D
    Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger.
    Gutiérrez-Cívicos R; Hurtado AM; Torres-Moreno D; Sanchez-Blanco JJ; Español I; Consuegra-Sánchez L; Perez-Ceballos E; Gutiérrez-Meca MD; Jerez A; Conesa-Zamora P
    Pharmacogenet Genomics; 2017 Feb; 27(2):70-77. PubMed ID: 27977511
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.